These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
299 related articles for article (PubMed ID: 28579139)
21. Pathologic Complete Response with Neoadjuvant Doxorubicin and Cyclophosphamide Followed by Paclitaxel with Trastuzumab and Pertuzumab in Patients with HER2-Positive Early Stage Breast Cancer: A Single Center Experience. Singh JC; Mamtani A; Barrio A; Morrow M; Sugarman S; Jones LW; Yu AF; Argolo D; Smyth LM; Modi S; Schweber S; Boafo C; Patil S; Norton L; Baselga J; Hudis CA; Dang C Oncologist; 2017 Feb; 22(2):139-143. PubMed ID: 28167568 [TBL] [Abstract][Full Text] [Related]
22. Randomized parallel study of doxorubicin plus paclitaxel and doxorubicin plus cyclophosphamide as neoadjuvant treatment of patients with breast cancer. Diéras V; Fumoleau P; Romieu G; Tubiana-Hulin M; Namer M; Mauriac L; Guastalla JP; Pujade-Lauraine E; Kerbrat P; Maillart P; Pénault-Llorca F; Buyse M; Pouillart P J Clin Oncol; 2004 Dec; 22(24):4958-65. PubMed ID: 15611510 [TBL] [Abstract][Full Text] [Related]
23. Pilot neoadjuvant trial in HER2 positive breast cancer with combination of nab-paclitaxel and lapatinib. Kaklamani VG; Siziopikou K; Scholtens D; Lacouture M; Gordon J; Uthe R; Meservey C; Hansen N; Khan SA; Jeruss JS; Bethke K; Cianfrocca M; Rosen S; Von Roenn J; Wayne J; Parimi V; Jovanovic B; Gradishar W Breast Cancer Res Treat; 2012 Apr; 132(3):833-42. PubMed ID: 21359953 [TBL] [Abstract][Full Text] [Related]
24. Comparing Neoadjuvant Nab-paclitaxel vs Paclitaxel Both Followed by Anthracycline Regimens in Women With ERBB2/HER2-Negative Breast Cancer-The Evaluating Treatment With Neoadjuvant Abraxane (ETNA) Trial: A Randomized Phase 3 Clinical Trial. Gianni L; Mansutti M; Anton A; Calvo L; Bisagni G; Bermejo B; Semiglazov V; Thill M; Chacon JI; Chan A; Morales S; Alvarez I; Plazaola A; Zambetti M; Redfern AD; Dittrich C; Dent RA; Magazzù D; De Fato R; Valagussa P; Tusquets I JAMA Oncol; 2018 Mar; 4(3):302-308. PubMed ID: 29327055 [TBL] [Abstract][Full Text] [Related]
25. Neoadjuvant Chemotherapy With Nab-paclitaxel Plus Trastuzumab Followed by 5-Fluorouracil/Epirubicin/Cyclophosphamide for HER2-positive Operable Breast Cancer: A Multicenter Phase II Trial. Tokunaga S; Takashima T; Kashiwagi S; Noda S; Kawajiri H; Tokumoto M; Nishimura S; Nishimori T; Ikeda K; Ogawa Y; Mizuyama Y; Sunami T; Tezuka K; Yamagata S; Ishikawa T; Kudoh S; Takada M; Hirakawa K; Ohira M Anticancer Res; 2019 Apr; 39(4):2053-2059. PubMed ID: 30952749 [TBL] [Abstract][Full Text] [Related]
26. Phase II trial of neoadjuvant weekly nanoparticle albumin-bound paclitaxel, carboplatin, and biweekly bevacizumab therapy in women with clinical stage II or III HER2-negative breast cancer. Mrózek E; Layman R; Ramaswamy B; Lustberg M; Vecchione A; Knopp MV; Shapiro CL Clin Breast Cancer; 2014 Aug; 14(4):228-34. PubMed ID: 24703985 [TBL] [Abstract][Full Text] [Related]
27. Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial. Robidoux A; Tang G; Rastogi P; Geyer CE; Azar CA; Atkins JN; Fehrenbacher L; Bear HD; Baez-Diaz L; Sarwar S; Margolese RG; Farrar WB; Brufsky AM; Shibata HR; Bandos H; Paik S; Costantino JP; Swain SM; Mamounas EP; Wolmark N Lancet Oncol; 2013 Nov; 14(12):1183-92. PubMed ID: 24095300 [TBL] [Abstract][Full Text] [Related]
28. Evaluation of changes in biologic markers ER, PR, HER 2 and Ki-67 index in breast cancer with administration of neoadjuvant dose dense doxorubicin, cyclophosphamide followed by paclitaxel chemotherapy. Dede DS; Gumuskaya B; Guler G; Onat D; Altundag K; Ozisik Y J BUON; 2013; 18(2):366-71. PubMed ID: 23818347 [TBL] [Abstract][Full Text] [Related]
29. Phase II study of neoadjuvant weekly nab-paclitaxel and carboplatin, with bevacizumab and trastuzumab, as treatment for women with locally advanced HER2+ breast cancer. Yardley DA; Raefsky E; Castillo R; Lahiry A; Locicero R; Thompson D; Shastry M; Burris HA; Hainsworth JD Clin Breast Cancer; 2011 Oct; 11(5):297-305. PubMed ID: 21729666 [TBL] [Abstract][Full Text] [Related]
30. [Efficacy and Safety of Nanoparticle Albumin-Bound Paclitaxel as Neoadjuvant Chemotherapy in Breast Cancer Patients]. Kang Y; Shiraki E; Tsuyuki S Gan To Kagaku Ryoho; 2019 Sep; 46(9):1427-1431. PubMed ID: 31530783 [TBL] [Abstract][Full Text] [Related]
31. Neoadjuvant doxorubicin/cyclophosphamide followed by ixabepilone or paclitaxel in early stage breast cancer and evaluation of βIII-tubulin expression as a predictive marker. Saura C; Tseng LM; Chan S; Chacko RT; Campone M; Manikhas A; Nag SM; Leichman CG; Dasappa L; Fasching PA; Hurtado de Mendoza F; Symmans WF; Liu D; Mukhopadhyay P; Horak C; Xing G; Pusztai L Oncologist; 2013; 18(7):787-94. PubMed ID: 23853246 [TBL] [Abstract][Full Text] [Related]
32. Evaluation of changes of biologic markers ER, PR, HER 2 and Ki-67 in breast cancer with administration of neoadjuvant dose-dense doxorubicin, cyclophosphamide followed by paclitaxel. Dede DS; Gumuskaya B; Guler G; Onat D; Altundag K; Ozisik Y J BUON; 2013; 18(1):57-63. PubMed ID: 23613389 [TBL] [Abstract][Full Text] [Related]
33. A feasibility study of bevacizumab plus dose-dense doxorubicin-cyclophosphamide (AC) followed by nanoparticle albumin-bound paclitaxel in early-stage breast cancer. McArthur HL; Rugo H; Nulsen B; Hawks L; Grothusen J; Melisko M; Moasser M; Paulson M; Traina T; Patil S; Zhou Q; Steingart R; Dang C; Morrow M; Cordeiro P; Fornier M; Park J; Seidman A; Lake D; Gilewski T; Theodoulou M; Modi S; D'Andrea G; Sklarin N; Robson M; Moynahan ME; Sugarman S; Sealey JE; Laragh JH; Merali C; Norton L; Hudis CA; Dickler MN Clin Cancer Res; 2011 May; 17(10):3398-407. PubMed ID: 21350003 [TBL] [Abstract][Full Text] [Related]
34. Comparison between nab-paclitaxel and solvent-based taxanes as neoadjuvant therapy in breast cancer: a systematic review and meta-analysis. Liu M; Liu S; Yang L; Wang S BMC Cancer; 2021 Feb; 21(1):118. PubMed ID: 33541289 [TBL] [Abstract][Full Text] [Related]
35. Proliferation Determined by Ki-67 Defines Different Pathologic Response to Neoadjuvant Trastuzumab-Based Chemotherapy in HER2-Positive Breast Cancer. Sánchez-Muñoz A; Navarro-Perez V; Plata-Fernández Y; Santonja A; Moreno I; Ribelles N; Alba E Clin Breast Cancer; 2015 Oct; 15(5):343-7. PubMed ID: 25752727 [TBL] [Abstract][Full Text] [Related]
36. Nab-paclitaxel/bevacizumab/carboplatin chemotherapy in first-line triple negative metastatic breast cancer. Hamilton E; Kimmick G; Hopkins J; Marcom PK; Rocha G; Welch R; Broadwater G; Blackwell K Clin Breast Cancer; 2013 Dec; 13(6):416-20. PubMed ID: 24099649 [TBL] [Abstract][Full Text] [Related]
37. Phase II trial of doxorubicin/docetaxel/cyclophosphamide for locally advanced and metastatic breast cancer: results from NSABP trial BP-58. Smith RE; Anderson SJ; Brown A; Scholnik AP; Desai AM; Kardinal CG; Lembersky BC; Mamounas EP Clin Breast Cancer; 2002 Dec; 3(5):333-40. PubMed ID: 12533263 [TBL] [Abstract][Full Text] [Related]
38. Neoadjuvant Chemotherapy in Patients with HER2-Negative Breast Cancer: A Report from Clinical Breast Cancer Registry of Iran. Roudini K; Mirzania M; Yavari T; Seyyedsalehi MS; Nahvijou A; Zebardast J; Saadat M; Khajeh-Mehrizi A Arch Iran Med; 2024 Apr; 27(4):206-215. PubMed ID: 38685847 [TBL] [Abstract][Full Text] [Related]
39. NAB-Paclitaxel Improves Disease-Free Survival in Early Breast Cancer: GBG 69-GeparSepto. Untch M; Jackisch C; Schneeweiss A; Schmatloch S; Aktas B; Denkert C; Schem C; Wiebringhaus H; Kümmel S; Warm M; Fasching PA; Just M; Hanusch C; Hackmann J; Blohmer JU; Rhiem K; Schmitt WD; Furlanetto J; Gerber B; Huober J; Nekljudova V; von Minckwitz G; Loibl S J Clin Oncol; 2019 Sep; 37(25):2226-2234. PubMed ID: 31082269 [TBL] [Abstract][Full Text] [Related]
40. Randomized phase II study of weekly paclitaxel with and without carboplatin followed by cyclophosphamide/epirubicin/5-fluorouracil as neoadjuvant chemotherapy for stage II/IIIA breast cancer without HER2 overexpression. Ando M; Yamauchi H; Aogi K; Shimizu S; Iwata H; Masuda N; Yamamoto N; Inoue K; Ohono S; Kuroi K; Hamano T; Sukigara T; Fujiwara Y Breast Cancer Res Treat; 2014 Jun; 145(2):401-9. PubMed ID: 24728578 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]